Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

41. Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause

Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause Management Briefs eBrief-no117 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no117 -- Health Services Research & Development Management eBrief no. 117 » Issue 117 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Report: Non-Pharmacologic Treatments (...) for Vasomotor Symptoms Associated with Menopause Vasomotor symptoms (VMS), which include hot flashes and night sweats, are the most common symptoms reported during the menopausal transition. VMS symptoms are experienced by as many as 80% of women with a mean age of onset of 51 years, and can last more than seven years. VMS can lead to increased healthcare encounters for symptom relief and reductions in quality of life. The degree to which VMS are bothersome is determined not only by how frequently

2016 Veterans Affairs - R&D

42. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis Full Text available with Trip Pro

Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis To test the hypothesis that effects of estrogen-containing hormone therapy on cognitive abilities differ between postmenopausal women near to, and further from, menopause.In this randomized, double-blind, placebo-controlled trial, healthy women within 6 years of menopause or 10+ years after menopause were randomly assigned to oral 17β-estradiol 1 mg/d or placebo. Women with a uterus received cyclic (...) in composite scores (-0.06, 95% confidence interval -0.22 to 0.09) was not significant (2-tailed p = 0.33). Differences were similar in early and late postmenopause groups (2-tailed interaction p = 0.88). Interactions between postmenopause groups and differences between treatment groups were not significant for executive functions or global cognition.Estradiol initiated within 6 years of menopause does not affect verbal memory, executive functions, or global cognition differently than therapy begun 10

2016 EvidenceUpdates Controlled trial quality: predicted high

43. Menopause Management - Getting Clinical Care Back on Track. Full Text available with Trip Pro

Menopause Management - Getting Clinical Care Back on Track. 26962899 2016 03 15 2018 12 02 1533-4406 374 9 2016 Mar 03 The New England journal of medicine N. Engl. J. Med. Menopause Management--Getting Clinical Care Back on Track. 803-6 10.1056/NEJMp1514242 Manson JoAnn E JE From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (J.E.M.); and the University of Florida College of Medicine, Jacksonville (A.M.K.). Kaunitz Andrew M AM From the Department (...) of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (J.E.M.); and the University of Florida College of Medicine, Jacksonville (A.M.K.). eng Journal Article United States N Engl J Med 0255562 0028-4793 AIM IM Hormone Replacement Therapy adverse effects statistics & numerical data Humans Internal Medicine education Internship and Residency Menopause drug effects Middle Aged Risk United States Women's Health 2016 3 11 6 0 2016 3 11 6 0 2016 3 16 6 0 ppublish 26962899 10.1056

2016 NEJM

44. Acupuncture for Menopausal Hot Flashes: A Randomized Trial. (Abstract)

Acupuncture for Menopausal Hot Flashes: A Randomized Trial. Hot flashes (HFs) affect up to 75% of menopausal women and pose a considerable health and financial burden. Evidence of acupuncture efficacy as an HF treatment is conflicting.To assess the efficacy of Chinese medicine acupuncture against sham acupuncture for menopausal HFs.Stratified, blind (participants, outcome assessors, and investigators, but not treating acupuncturists), parallel, randomized, sham-controlled trial with equal (...) allocation. (Australia New Zealand Clinical Trials Registry: ACTRN12611000393954).Community in Australia.Women older than 40 years in the late menopausal transition or postmenopause with at least 7 moderate HFs daily, meeting criteria for Chinese medicine diagnosis of kidney yin deficiency.10 treatments over 8 weeks of either standardized Chinese medicine needle acupuncture designed to treat kidney yin deficiency or noninsertive sham acupuncture.The primary outcome was HF score at the end of treatment

2016 Annals of Internal Medicine Controlled trial quality: predicted high

45. Menopausal hormone therapy: in addition to other risks, an increased risk of ovarian cancer

Menopausal hormone therapy: in addition to other risks, an increased risk of ovarian cancer Prescrire IN ENGLISH - Spotlight ''Menopausal hormone therapy: in addition to other risks, an increased risk of ovarian cancer'', 1 January 2016 {1} {1} {1} | | > > > Menopausal hormone therapy: in addition to other risks, an increased risk of ovarian cancer Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Menopausal hormone therapy: in addition to other risks, an increased risk of ovarian cancer The harm-benefit balance for hormone replacement therapy in menopause is unfavourable due to an increased risk of cardiovascular disease and of breast cancer. It also exposes women to ovarian cancer. At the beginning of 2015, a review of 52 epidemiological studies showed a statistically significant risk of ovarian cancer in women exposed to menopausal

2016 Prescrire

46. Canadian Consensus on Female Nutrition: Adolescence, Reproduction, Menopause, and Beyond

Canadian Consensus on Female Nutrition: Adolescence, Reproduction, Menopause, and Beyond Canadian Consensus on Female Nutrition: Adolescence, Reproduction, Menopause, and Beyond - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 38, Issue 6, Pages 508–554.e18 Canadian Consensus on Female Nutrition: Adolescence, Reproduction, Menopause, and Beyond Nutrition Working Group x Deborah L. O'Connor , PhD, RD (Principal Author (...) ; FSH, follicle-stimulating hormone; AMH, anti-mullerian hormone Abstract Objectives To provide health care professionals in Canada with the basic knowledge and tools to provide nutrition guidance to women through their lifecycle. Outcomes Optimal nutrition through the female lifecycle was evaluated, with specific focus on adolescence, pre-conception, pregnancy, postpartum, menopause, and beyond. The guideline begins with an overview of guidance for all women, followed by chapters that examine

2016 Society of Obstetricians and Gynaecologists of Canada

47. Managing menopausal symptoms after breast cancer - a guide for women

Managing menopausal symptoms after breast cancer - a guide for women A guide for women Managing menopausal symptoms after breast cancerManaging menopausal symptoms after breast cancer A guide for womenBreast cancer and early menopause — a guide for younger women First edition published in 2008 by: National Breast and Ovarian Cancer Centre*. Managing menopausal symptoms after breast cancer Second edition published in 2016 by Cancer Australia Locked Bag 3, Strawberry Hills NSW 2012 Tel: 61 2 9357 (...) 9400 Fax: 61 2 9357 9477 canceraustralia.gov.au © Cancer Australia 2016 ISBN Print: 978-1-74127-252-9 Online: 978-1-74127-253-6 CIP: 616.99449 Recommended citation: Cancer Australia. Managing menopausal symptoms after breast cancer. Cancer Australia, Surry Hills, NSW, 2012. Managing menopausal symptoms after breast cancer, can be downloaded or ordered from the Cancer Australia website: canceraustralia.gov.au/resources Copyright statements Paper-based publications This work is copyright. You may

2016 Cancer Australia

48. Limited Evidence Suggests Oral Health Providers Should Observe Caution When Treating Post-Menopausal Women Taking Aromatase Inhibitor (AI) Drugs or Estrogen Modulating Agents

Limited Evidence Suggests Oral Health Providers Should Observe Caution When Treating Post-Menopausal Women Taking Aromatase Inhibitor (AI) Drugs or Estrogen Modulating Agents UTCAT2949, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Limited Evidence Suggests Oral Health Providers Should Observe Caution When Treating Post-Menopausal Women Taking Aromatase Inhibitor (AI) Drugs or Estrogen Modulating Agents Clinical (...) Question Is there an increased risk of alveolar bone loss and dental-related complications in post-menopausal women taking aromatase inhibitor drugs or estrogen/progesterone modulator agents? Clinical Bottom Line Special consideration should be taken regarding the treatment of post-menopausal women taking aromatase inhibitor (AI) drugs. In particular, this includes monitoring periodontal disease, patients undergoing dentoalveolar surgery, and monitoring bone density. Evidence suggests appreciable loss

2015 UTHSCSA Dental School CAT Library

49. Examining the psychometric properties of the brief 'Menopausal Symptoms Distress Affecting Sleep Quality Scale' (Abstract)

Examining the psychometric properties of the brief 'Menopausal Symptoms Distress Affecting Sleep Quality Scale' To examine the psychometric properties of the Menopausal Symptoms Distress Affecting Sleep Quality Scale.Sleep disturbances are an extensive and common problem among menopausal women. However, no unique and specific scale has yet been developed to detect the inductive symptoms distresses that cause poor sleep quality for menopausal women.A cross-sectional design.The Menopausal (...) Symptoms Distress Affecting Sleep Quality Scale was based on in-depth interviews with menopausal women and literature review. Convenience sampling was employed. One hundred and fifty three women participated in this study. Exploratory factor analysis, concurrent validity and contrasting group validity were used to examine the validity of the Menopausal Symptoms Distress Affecting Sleep Quality Scale. Cronbach's α was conducted to test the reliability. The accuracy of the scale was analysed

2015 EvidenceUpdates

50. Periodontal treatment outcomes in post menopausal women receiving hormone replacement therapy Full Text available with Trip Pro

Periodontal treatment outcomes in post menopausal women receiving hormone replacement therapy To evaluate the effect of hormone replacement therapy(HRT) on periodontal treatment outcomes in a group of postmenopausal women with periodontitis.23 post-menopausal chronic periodontitis patients were included in this study. The test group(n=11) consisted of women who started HRT with this study and received conjugated estrogen and medroxyprogesteron. The control group(n=12) was women not taking any

2015 Journal of Istanbul University Faculty of Dentistry Controlled trial quality: uncertain

51. No sex please, we’re menopausal!

No sex please, we’re menopausal! No sex please, we're menopausal! - Evidently Cochrane Search and hit Go By March 13, 2015 // In today’s guest blog, Elaine Miller, a physiotherapist who also does a stand-up comedy show about pelvic floors, tackles sex and the menopause. I have a faded post-it note on my office wall that says “what most people need is a really good listening to”. It’s sound advice for life, but, particularly useful whenever a patient brings up a sexual function issue in clinic (...) . Menopausal women often experience changes in how they think about their bodies and sexuality. Many have sad feelings about the loss of fertility and the body of their youth. Of course, some women relish not fearing unwanted pregnancy and finally feeling comfortable in their own skin. Elaine Miller, tackling the taboo with humour and reliable information. Sexuality is not just about having sex, and sex is about more than penetration. A lack of intimacy, in whatever form, negatively impacts our wellbeing

2015 Evidently Cochrane

52. Hormone Therapy for the Menopause after Endometriosis Surgery – Friend or Foe?

Hormone Therapy for the Menopause after Endometriosis Surgery – Friend or Foe? Hormone Therapy for the Menopause after Endometriosis Surgery - Friend or Foe? - Evidently Cochrane Search and hit Go By March 12, 2015 // In today’s guest blog, Dr Martin Hirsch explains about endometriosis and treatment choices for women who have the menopause induced because of it. It’s Menopause Week here at Evidently Cochrane and as a team including individual bloggers, Cochrane UK, Healthtalk and Menopause UK (...) with their NHS Change Day campaign to ‘Change the Change’, we are summarising the evidence surrounding the menopause to ensure women get the correct facts from reliable evidence. This blog aims to help women who have had the menopause induced through surgery for endometriosis make more informed health decisions at a time of significant change for their mind and body. Endometriosis – what is it and how do I know if I have it? Most women have heard of the menopause. They fear it, but for a select few women

2015 Evidently Cochrane

53. Everything I needed to know about the menopause… No One Told Me

Everything I needed to know about the menopause… No One Told Me Everything I needed to know about the menopause... No One Told Me - Evidently Cochrane Search and hit Go By March 11, 2015 // Today’s guest blog comes from Oxford academic June Girvin, who shares her experiences of the menopause, the taboo and the information gap. Today is NHS Change Day and June, along with the rest of our guest bloggers in this special series on the menopause, is backing Menopause UK’s grassroots campaign (...) for Change Day to #changethechange. You can read more about that here. It’s Menopause Week on Evidently Cochrane. I wasn’t sure whether that required an exclamation mark, but decided, all things considered, that it didn’t. My contribution to this week of menopause related blogs is a personal one – or a phenomenological one as this is a blog for ‘Evidently Cochrane’ – and I think my lived experience of the ‘last taboo’ or the ‘Big M’ (thankfully one rarely hears it called ‘THE CHANGE’ anymore with all its

2015 Evidently Cochrane

54. Let’s talk about the menopause

Let’s talk about the menopause Let's talk about the menopause - Evidently Cochrane Search and hit Go By March 6, 2015 // In the first of our series of guest blogs about the menopause and health, Jenny Hislop , a Senior Qualitative Researcher in the (HERG) at the University of Oxford, talks about her research on the menopause and collecting women’s stories for the website. The website healthtalk.org “brings the menopause into the open.” A few years ago I had the privilege of interviewing 46 (...) women throughout the UK about their experiences of the menopause for the award-winning website What impressed me most was their willingness to talk openly about the menopause and its impact on their everyday lives. And it takes courage to do this. We live in a society where we tend to build a wall of silence around personal matters like the menopause – it’s something we keep hidden and as a result no one really knows what to expect. And I think this is one of the key strengths of the menopause site

2015 Evidently Cochrane

55. Making sense of the menopause: experience, evidence and you

Making sense of the menopause: experience, evidence and you Making sense of the menopause: experience, evidence and you - Evidently Cochrane Search and hit Go By March 6, 2015 // Let’s talk about the menopause. We really need to! We’ve designated next week Menopause Week on Evidently Cochrane and this afternoon we start a series of six guest blogs on the menopause, from women brave enough to share their experiences and doctors and researchers with the latest evidence on treatments. We’re also (...) supporting in their actions for NHS Change Day on March 11th which they hope will #changethechange. It’s unthinkable that we wouldn’t tell girls about menstruation, yet this other stage in women’s lives is not freely discussed and women are arriving at it unprepared. This isn’t so in all cultures and in those where aging conveys status the menopause is often treated rather differently. Louise Foxcroft has noted, in her excellent book on the modern menopause, that modern Jewish Orthodox practice has begun

2015 Evidently Cochrane

56. Menopausal Symptoms: Comparative Effectiveness of Therapies

Menopausal Symptoms: Comparative Effectiveness of Therapies Menopausal Symptoms: Comparative Effectiveness of Therapies Comparative Effectiveness Review Number 147Comparative Effectiveness Review Number 147 Menopausal Symptoms: Comparative Effectiveness of Therapies Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10058-I Prepared by: Blue Cross and Blue Shield (...) presented in this report. Suggested citation: Grant MD, Marbella A, Wang AT, Pines E, Hoag J, Bonnell C, Ziegler KM, Aronson N. Menopausal Symptoms: Comparative Effectiveness of Therapies. Comparative Effectiveness Review No. 147. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007- 10058-I.) AHRQ Publication No. 15-EHC005-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2015

2015 Effective Health Care Program (AHRQ)

57. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition Full Text available with Trip Pro

Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition The expected duration of menopausal vasomotor symptoms (VMS) is important to women making decisions about possible treatments.To determine total duration of frequent VMS (≥ 6 days in the previous 2 weeks) (hereafter total VMS duration) during the menopausal transition, to quantify how long frequent VMS persist after the final menstrual period (FMP) (hereafter post-FMP persistence), and to identify risk factors for longer (...) total VMS duration and longer post-FMP persistence.The Study of Women's Health Across the Nation (SWAN) is a multiracial/multiethnic observational study of the menopausal transition among 3302 women enrolled at 7 US sites. From February 1996 through April 2013, women completed a median of 13 visits. Analyses included 1449 women with frequent VMS.Total VMS duration (in years) (hot flashes or night sweats) and post-FMP persistence (in years) into postmenopause.The median total VMS duration was 7.4

2015 EvidenceUpdates

58. Dehydroepiandrosterone for the Treatment of Menopausal or Andropausal Symptoms

Dehydroepiandrosterone for the Treatment of Menopausal or Andropausal Symptoms Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) of Menopausal or Andropausal Symptoms: Clinical Effectiveness and Safety DATE: 25 February 2015 RESEARCH QUESTION What is the clinical effectiveness and safety of dehydroepiandosterone (DHEA) for the treatment of menopausal or andropausal symptoms? KEY FINDINGS Two systematic reviews, two randomized controlled trials, and one non-randomized study were identified regarding the clinical effectiveness and safety of DHEA for the treatment of menopausal symptoms; no evidence was identified regarding DHEA

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

59. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial Full Text available with Trip Pro

The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial To investigate the effectiveness of exercise as treatment for vasomotor menopausal symptoms.Three-group randomised controlled trial, two exercise interventions and a control group.Primary Care, West Midlands UK.Perimenopausal and postmenopausal women experiencing at least five hot flushes/night sweats per day and not taken MHT in previous 3 months were recruited from 23 general (...) practices.Participants in both exercise interventions groups were offered two face-to-face consultations with a physical activity facilitator to support engagement in regular exercise. In addition, one exercise group received a menopause-specific information DVD and written materials to encourage regular exercise and the other exercise group was offered the opportunity to attend exercise social support groups in their communities. Interventions lasted 6 months.The primary outcome was frequency of hot flushes/night

2015 EvidenceUpdates Controlled trial quality: uncertain

60. Menopause: diagnosis and management

Menopause: diagnosis and management Menopause: diagnosis and management Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Menopause: diagnosis and management (NG23) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 30Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Individualised care 5 1.2 Diagnosis

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines